A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621 a Novel Biologic Targeting CD47 in Subjects with Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors

Brief description of study

If you have been diagnosed with Lymphoma, Leukemia, Myelodysplastic syndrome, Myeloproliferative neoplasms, or Multiple myeloma, that has returned or worsened since your previous treatment, you may be qualified for this Phase Ia/Ib study evaluating the investigational drug TTI-621. The main goal of this study is to test the safety of TTI-621 when it is given in combination with other anti-cancer drugs, rituximab or nivolumab.


Clinical Study Identifier: s17-01012
ClinicalTrials.gov Identifier: NCT02663518
Principal Investigator: Catherine M Diefenbach
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.